TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04172844
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg on cycle 1 day 1, 200 mg daily on cycle 1 day 2, 400 mg on cycle 1 day 3 and thereafter from cycle 1. Venetoclax is given for a minimum of 21 days and a maximum of 28 days. Administered orally.
Study: NCT04172844
Drug: Pevonedistat
Normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
Study: NCT02047461
Drug: ORGN001 (formerly ALXN1101)
Normalized name: Lor-253(former code)
DrugBank: APTO-253 (DB17143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT01382810
Drug: Altaire Gel forming solution
Normalized name: sodium chloride Nasal Solution [SaltAire]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three times a day for two months
Study: NCT01382810
Drug: Refresh Tears
Normalized name: Refresh Tears
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times a day for two months
Study: NCT01564875
Drug: Zocor
Normalized name: Zocor
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m.
Study: NCT00543725
Drug: efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg tablet once daily for 96 weeks
Study: NCT04109690
Drug: CPX-351
Normalized name: CPX
DrugBank: DPCPX (DB12946)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in both Phase I and II can receive a maximum of two induction and six consolidation cycles on an inpatient or outpatient basis per local hospital standard of care.
Study: NCT00431496
Drug: Cinacalcet
Normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cinacalcet tablets
Study: NCT01857024
Drug: sevelamer carbonate (Renvela®)
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800 mg tablets or 2.4 g powder for oral suspension should be administered as instructed in the Renvela® SmPC.
Study: NCT00801138
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 ml 0.9% saline (placebo)
Study: NCT00801138
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone 8 mg (2 ml)
Study: NCT00801138
Drug: ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 ml 0.5% ropivacaine
Study: NCT00801138
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 ml 0.5% bupivacaine
Study: NCT00788918
Drug: Interferon and ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Interferon 180 microgram weekly s.c. and ribavirin (800/100/1200 mg daily) p.o.
Study: NCT01005199
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily
Study: NCT01005199
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 2 x 400 mg daily
Study: NCT01983878
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT02630472
Drug: Quinine Sulfate
Normalized name: Quinine Sulfate
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Our plan is to first study quinine against saline to determine efficacy and safety. The vast majority of patients with rhinosinusitis utilize low pressure / high volume (240mls) sinonasal lavage to cleanse the sinonasal cavity. The patients will be exposed to a maximum of 12mls or 12.0 mg of quinine. In standard tonic water, quinine is 8.3mg/100mls and thus an 8oz glass of Canada Dry tonic water has 19.6mg of quinine. Thus, the maximum systemic exposure in our study (assuming ingestion of the total nasal administration) is less than drinking one glass of tonic water / day. To put this in context, the therapeutic range of quinine to treat malaria is 10mg/kg true ileal digestibility (TID) (2100mg for a 70kg individual) nearly 200 X the dose the investigators are proposing.
Study: NCT03158324
Drug: OPB-111077
Normalized name: OPB-111077
DrugBank: OPB-111077 (DB16630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive 600 mg of OPB-111077 on a 4 days-on, 3 days-off per week in 28-day cycles till disease progression or intolerable toxicity
Study: NCT00002984
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be given at a dose of 100 mg/m2 at a concentration of 1 mg/ml over one hour on Day 1 and 29 for a total of 2 courses
Study: NCT00002984
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30 mg/m2 - 45 mg/m2 given weekly. The dose each subject receives will depend on when they enter the study
Study: NCT01999400
Drug: Pentasa 500 mg capsule x 2 with 240 mL water; single dose
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01999400
Drug: Apriso 375 mg capsule x 3 with 240 mL water; single dose
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01999400
Drug: Lialda 1200 mg tablet x 1 with 240 mL water; single dose
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01999400
Drug: Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01423292
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 bupivacaine 30ml (15ml on each side)
Study: NCT01526603
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin intravenously (IV), 425 mg/m2/dose (or if ≤ 12kg, 14.2 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant.
Study: NCT03777085
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
Study: NCT00845845
Drug: Omega-3-acid ethyl esters (Lovaza)
Normalized name: Omega-3-Acid Ethyl Esters
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 milligrams daily omega-3-acid ethyl esters (Lovaza) with dietary counseling for 24 weeks.
Study: NCT02169713
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT02169713
Drug: Solifenacin succinate
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT02169713
Drug: Tamsulosin HCl
Normalized name: tamsulosin HCl
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT00526591
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive arm-specific dosage of Everolimus daily continuously for 8 week
Study: NCT00313105
Drug: Smokeless tobacco (Oliver Twist pellets)
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: individual visits with counseling
Study: NCT00356967
Drug: dianicline
Normalized name: Dianicline
DrugBank: Dianicline (DB12125)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01401517
Drug: sodium nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.
Study: NCT00412243
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 40 mg/m\^2 Daily for 3 Days
Study: NCT01526603
Drug: Isotretinoin (13-cis-retinoic acid)
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-transplant maintenance therapy with cis-RA daily for 14 days every 28 days repeated for 6 months. This phase of the therapy can be initiated by the BMT team and continued by the referring physician. It is recommended to begin Isotretinoin at day 66 post-transplant and no later than day 100. For patients ≤12 kg, isotretinoin (accutane) should be administered at 5.33 mg/kg/dose divided twice daily. For patients \>12 kg isotretinoin (accutane) should be administered at 160 mg/m\^2/day divided twice a day. Patients should be considered for monoclonal antibody therapy against GD2, such as ch14.18 if such trials are available.
Study: NCT01526603
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan Intravenously (IV), 70 mg/m2/dose (or if ≤ 12 kg, 2.3 mg/kg/dose) once daily x 3 doses on days 7 through 5 pretransplant
Study: NCT01526603
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide intravenously (IV), 338 mg/m2/dose (or if ≤ 12kg, 11.3 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant
Study: NCT00906698
Drug: BIBW 2992 low (20mg) dosage
Normalized name: ethinyl estradiol
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 20mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
Study: NCT00906698
Drug: BIBW 2992 medium (40mg) dosage
Normalized name: Medium-Chain Triglycerides
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 40mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
Study: NCT00906698
Drug: BIBW 2992 high (50mg) dosage
Normalized name: high-density polyethylene
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 50mg dosage of BIBW 2992 plus standard dosage of vinorelbine.
Study: NCT00906698
Drug: Vinorelbine per os 80 mg/m²
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 80 mg/m² Vinorelbine per os at J22
Study: NCT00906698
Drug: Vinorelbine i.v. 25 mg/m²
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 25 mg/m² of Vinorelbine i.v.
Study: NCT04440943
Drug: CDX-527
Normalized name: CDX
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDX-527 is administered by infusion every 2 weeks
Study: NCT01674569
Drug: ranibizumab (Lucentis)
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rescue treatment with intravitreal ranibizumab (Lucentis) as needed
Study: NCT02430181
Drug: lonafarnib
Normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antiviral farnesyl transferase inhibitor
Study: NCT02430181
Drug: peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: immunomodulator
Study: NCT02430181
Drug: ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CYP 3A4 inhibitor, lonafarnib booster
Study: NCT03054220
Drug: Dextromethorphan 5 MG
Normalized name: dextromethorphan 5 mg oral lozenge
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03316638
Drug: W0101 - Cohort A1
Normalized name: Zygomycin A1
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered once every 2 weeks
Study: NCT03054220
Drug: Duloxetine 60mg
Normalized name: DULOXETINE 60MG CAP,SPRINKLE,EC
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03054220
Drug: Paroxetine 20 mg
Normalized name: PARoxetine 20 mg oral tablet
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03014687
Drug: Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral antibiotics (cefdinir \[Omnicef®\] 300 mg PO BID or trimethoprim/sulfamethoxazole \[Bactrim DS™\] PO BID for cephalosporin intolerant patients) for 7 days.Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
Study: NCT01960179
Drug: lixisenatide AVE0010
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:solution Route of administration: Subcutaneous injection
Study: NCT02690103
Drug: pegylated IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months.
Study: NCT02690103
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin is prescribed according to patients body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
Study: NCT02824003
Drug: ISIS-GCGRRx
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once weekly dosing for 13 weeks
Study: NCT02393898
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be prescribed by the local clinician according to the SmPC and standard of care for up to 15 months. No treatment will be provided by the Sponsor in this non-interventional study.
Study: NCT02393898
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
Study: NCT02393898
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
Study: NCT02272517
Drug: Vortioxetine 10-20 mg
Normalized name: vortioxetine 20 MG
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02272517
Drug: Escitalopram 10-20 mg
Normalized name: escitalopram 20 MG
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00589732
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan 160mg per day
Study: NCT00864682
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.3 mL normal saline
Study: NCT00864682
Drug: Lidocaine / propofol admixture
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine 50 mg plus propofol 50 mg intravenous (iv)
Study: NCT00864682
Drug: lidocaine pretreatment
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine 50 mg iv under tourniquet-control
Study: NCT00545844
Drug: montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: montelukast sodium, 10 mg, one tablet once a day for 8 weeks as add on therapy to usual current asthma controller treatment
Study: NCT01982643
Drug: naltrexone plus bupropion
Normalized name: bupropion / naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks.
Study: NCT03736785
Drug: Insulin Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC
Study: NCT02974010
Drug: NRX-101 Oral Capsule
Normalized name: NRX-1074
DrugBank: NRX-1074 (DB11784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prospective Randomized Factorial Design Study as per arm/group descriptions
Study: NCT02974010
Drug: Lurasidone Oral Capsule
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prospective Randomized Factorial Design Study as per arm/group descriptions
Study: NCT02974010
Drug: Ketamine Intravenous Infusion
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
Study: NCT01594502
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg daily
Study: NCT01744691
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All subjects will receive ibrutinib 420 mg (3 x 140-mg capsules) orally once daily.
Study: NCT02837380
Drug: FF
Normalized name: MFF
DrugBank: Melphalan flufenamide (DB16627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FF is a dry white powder blended with lactose. It is the first strip of DPI. Per blister contains 100 mcg of dose
Study: NCT03742713
Drug: CPC634 (CriPec® docetaxel)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel containing CriPec® nanoparticles
Study: NCT01026142
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 840 mg iv loading, then 420 mg iv every 3 weeks
Study: NCT00413790
Drug: Darifenacin
Normalized name: Darifenacin
DrugBank: Darifenacin (DB00496)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Darifenacin tablets 15 mg once daily
Study: NCT00413790
Drug: Tolterodine
Normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolterodine extended release (ER) 4 mg once daily
Study: NCT01026142
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks
Study: NCT04052568
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will undergo up to four moderate to high dose psilocybin sessions. Dosing at the first session will be 20 mg. For subsequent sessions participants will either remain at their previous dose, or increase by increments of 5 mg up to a maximum of 30 mg.
Study: NCT00411372
Drug: fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02429622
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel from 45 to 60 mg/m2 per week concurrent with radiotherapy for 5weeks
Study: NCT02429622
Drug: Nedaplatin
Normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedaplatin 25mg/m2 per week concurrent with radiotherapy for 5weeks
Study: NCT04120961
Drug: prolonged continuous use of bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prolonged continuous use of bivalirudin 4 hours after elective PCI (dose: 0.75 mg/kg bolus plus 1.75 mg/kg per hour)
Study: NCT04120961
Drug: bivalirudin use during ePCI
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bivalirudin use during ePCI (0.75 mg/kg bolus plus 1.75 mg/kg per hour)
Study: NCT00366691
Drug: Acular LS
Normalized name: Acular LS
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00366691
Drug: Lotemax
Normalized name: Lotemax
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00972725
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One dose of 300 mg
Study: NCT03681951
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be available as solution for infusion (100 milligrams/ 4 milliliter) at a dose of 200 mg via IV infusion for 30 minutes (given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted i.e., infusion time is 25 to 40 minutes).
Study: NCT02187809
Drug: Clobazam
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00728481
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks
Study: NCT01578655
Drug: cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel (25mg/m² IV) is administered on day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
Study: NCT01578655
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (10 mg PO) is administered daily until disease progression, unacceptable toxicity, or completion of 10 cycles
Study: NCT01578655
Drug: custirsen sodium
Normalized name: Custirsen
DrugBank: Custirsen (DB05487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custirsen is administered as 3 loading doses (640 mg IV each) within 9 days, followed by weekly custirsen (640 mg IV) during each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
Study: NCT01103583
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/die per os for two years
Study: NCT01076530
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01076530
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes